{"id":20726,"date":"2021-05-24T19:45:09","date_gmt":"2021-05-24T19:45:09","guid":{"rendered":"https:\/\/evaggelatos.com\/?p=20726"},"modified":"2021-05-24T19:45:09","modified_gmt":"2021-05-24T19:45:09","slug":"%cf%84%ce%b1-%ce%b5%ce%bc%ce%b2%cf%8c%ce%bb%ce%b9%ce%b1-%ce%b5%ce%bd%ce%ac%ce%bd%cf%84%ce%b9%ce%b1-%cf%83%cf%84%ce%bf%ce%bd-covid-19-%ce%b8%ce%b1-%cf%87%cf%81%ce%b5%ce%b9%ce%ac%ce%b6%ce%bf%ce%bd%cf%84","status":"publish","type":"post","link":"https:\/\/evaggelatos.com\/?p=20726","title":{"rendered":"\u03a4\u03b1 \u03b5\u03bc\u03b2\u03cc\u03bb\u03b9\u03b1 \u03b5\u03bd\u03ac\u03bd\u03c4\u03b9\u03b1 \u03c3\u03c4\u03bf\u03bd COVID-19 \u03b8\u03b1 \u03c7\u03c1\u03b5\u03b9\u03ac\u03b6\u03bf\u03bd\u03c4\u03b1\u03b9 \u03ba\u03b1\u03c4\u03ac \u03c0\u03b5\u03c1\u03b9\u03cc\u03b4\u03bf\u03c5\u03c2 \u03b1\u03bd\u03b1\u03b2\u03ac\u03b8\u03bc\u03b9\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03c4\u03b9\u03c2 \u03c0\u03c1\u03bf\u03ba\u03cd\u03c0\u03c4\u03bf\u03c5\u03c3\u03b5\u03c2 \u03bc\u03b5\u03c4\u03b1\u03bb\u03bb\u03ac\u03be\u03b5\u03b9\u03c2. \u0394\u03b7\u03bb\u03b1\u03b4\u03ae \u03b8\u03b1 \u03ba\u03ac\u03bd\u03bf\u03c5\u03bc\u03b5 \u03ba\u03ac\u03b8\u03b5 \u03c7\u03c1\u03cc\u03bd\u03bf \u03c4\u03bf\u03c5\u03bb\u03ac\u03c7\u03b9\u03c3\u03c4\u03bf\u03bd 2-3 \u03b4\u03cc\u03c3\u03b5\u03b9\u03c2"},"content":{"rendered":"

COVID-19 vaccines may need regular <\/span>updates for emerging variants<\/span><\/strong><\/span><\/p>\n

The Rockfeller University<\/strong><\/span><\/p>\n

\"\"<\/a>January 29, 2021<\/span><\/p>\n

Soon after the world\u2019s first COVID-19 vaccination campaigns kicked off, news emerged <\/span>about new, more contagious SARS-CoV-2 variants crisscrossing the planet. The <\/span>discovery of such strains in Britain, Brazil, and South Africa has raised a pressing <\/span>concern: Will current vaccines be effective against them?<\/span>This news story has been updated to reflect the publication of the study, previously <\/span>available on BioRxiv, in a peer-reviewed journal.<\/span><\/p>\n

In studying blood samples from people vaccinated with either Moderna\u2019s or Pfizer\u2019s<\/span>COVID-19 vaccine, Rockefeller scientists in the <\/span>Paul Bieniasz<\/span> and <\/span>Michel C.<\/span>Nussenzweig<\/span>\u2018s laboratories have arrived at a nuanced answer. Their findings show that <\/strong><\/span>the vaccines have less power to neutralize these new variants than the original Wuhan<\/span>strain, but could still offer crucial protection.<\/span><\/strong><\/div>\n
<\/div>\n
\u201cReduced neutralization does not mean no immunity. The vaccines will likely still prevent <\/span>severe disease,\u201d says Nussenzweig, the Zanvil A. Cohn and Ralph M. Steinman <\/span>Professor and head of the Laboratory of Molecular Immunology at Rockefeller. \u201cBut these <\/span>results mean that we will need to monitor newly arising variants to keep up with the<\/strong><\/span>virus\u2019s evolution, and that the vaccines may be need to be updated periodically.<\/strong>\u201d<\/span><\/div>\n
<\/div>\n
The <\/span>findings are available on bioRxiv<\/span> ahead of peer-review in scientific journals. <\/span>From vaccines to antibody drugs t<\/span>he new coronavirus variants have been shown to carry specific mutations, allowing <\/span>them to \u201cescape\u201d some of the neutralizing antibodies the body uses to fight off Covid-19.<\/span>In lab experiments, the researchers tested the impact of these mutations by letting <\/span>various versions of the coronavirus infect human cells in the presence of blood plasma <\/span>from 20 volunteers who had received either the Moderna or the Pfizer vaccine.<\/span><\/div>\n
<\/div>\n
The vaccines, the researchers found, had triggered the body to produce a broad range of <\/span>antibodies, including potent neutralizing antibodies known to be present in the blood <\/span><\/strong>plasma of people who have recovered from COVID-19.<\/strong> <\/span><\/div>\n
<\/div>\n
For the Wuhan strain, the plasma <\/span>samples of vaccinated people showed neutralizing activity similar to that which arises in <\/span>natural infection. For mutated viruses, however, the plasma samples showed a one to <\/span>three-fold decrease in neutralizing activity.<\/span><\/div>\n
<\/div>\n
\u201cThis is a modest reduction that should not render the vaccines ineffective, although it <\/span>could become a problem if the variants become dominant,\u201d says Zijun Wang, a postdoc <\/span>in Nussenzweig\u2019s lab and the study\u2019s first author.<\/span><\/div>\n
<\/div>\n
But the findings could have more immediate bearings on the development of monoclonal <\/span>antibody drugs\u2014treatments that, unlike vaccines, rely exclusively on the neutralizing <\/span>prowess (\u03b5\u03be\u03bf\u03c5\u03b4\u03b5\u03c4\u03b5\u03c1\u03c9\u03c4\u03b9\u03ba\u03ae \u03b9\u03c3\u03c7\u03cd) of specific antibodies. A number of antibody drugs for COVID-19 are currently <\/span>being tested in clinical trials, including <\/span>an antibody combination developed in <\/span>Nussenzweig\u2019s lab<\/span>.<\/span><\/div>\n
<\/div>\n
To find out how such treatments might perform on the emerging strains, the team isolated <\/span>and cloned some of the most potent antibodies from the volunteers and tested each <\/span>against the mutant viruses. Fourteen of 17 antibodies tested showed at least a ten-fold <\/span>reduction in their ability to neutralize corona viruses carrying major mutations found in the <\/span>variants from Britain, South Africa, and Brazil.<\/span><\/div>\n

 <\/p>\n

These findings underscore that monoclonal antibody drugs will not only have to be <\/span>continuously tested against the emerging variants, but should ideally be <\/span>developed as <\/span>multi-antibody treatments<\/span> in the first place, rather than being based on one antibody <\/span>alone. The drug discovered at Rockefeller was designed as a cocktail of two antibodies <\/span>recognizing different portions of SARS-CoV-2, reducing its risk of becoming ineffective <\/span>as the virus mutates<\/span><\/p>\n

Source:file:\/\/\/C:\/Users\/xaris\/OneDrive\/%CE%88%CE%B3%CE%B3%CF%81%CE%B1%CF%86%CE%B1\/Rockfeller%20University%20research%20on%20Covid-19.pdf<\/p>\n

https:\/\/diodotos-k-t.blogspot.com\/2021\/05\/k-alert-tv-43-rockefeller-university.html#more<\/p>\n

Comments:<\/p>\n

More than 25 labs are conducting research on the coronavirus<\/h3>\n

In response to the global COVID-19 pandemic, The Rockefeller University has launched numerous studies aimed at better understanding the biology of the SARS-CoV-2 virus and developing interventions to prevent and treat infections. Coronavirus-related projects have been launched in approximately one-fourth of the university\u2019s labs, including those run by leaders in fields such as virology, immunology, genomics, structural biology, and many other fields.<\/p>\n

Rockefeller scientists have been working to develop novel treatments and improved testing protocols, and are focused both on SARS-CoV-2 and other coronaviruses that may emerge in the future. Projects include the development of antibodies and other therapeutics capable of preventing or treating the infection; the search for small molecules that inhibit the activity of viral or human proteins required for viral replication; and the creation of new in vitro systems for testing potential treatments.<\/strong><\/span> Scientists are also taking several approaches to identify new vulnerabilities of the virus, including genomic studies of humans with unusual responses to infection and cell-based screens using CRISPR gene-editing technology.<\/p>\n","protected":false},"excerpt":{"rendered":"

COVID-19 vaccines may need regular updates for emerging variants The Rockfeller University January 29, 2021 Soon after the world\u2019s first COVID-19 vaccination campaigns kicked off, news emerged about new, more contagious SARS-CoV-2 variants crisscrossing the planet. The discovery of such strains in Britain, Brazil, and South Africa has raised a pressing concern: Will current vaccines … <\/p>\n

\u03a3\u03c5\u03bd\u03ad\u03c7\u03b5\u03b9\u03b1 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[85,41,10],"tags":[90],"class_list":["post-20726","post","type-post","status-publish","format-standard","hentry","category-85","category-41","category-10","tag-90","item-wrap"],"_links":{"self":[{"href":"https:\/\/evaggelatos.com\/index.php?rest_route=\/wp\/v2\/posts\/20726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/evaggelatos.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/evaggelatos.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/evaggelatos.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/evaggelatos.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20726"}],"version-history":[{"count":2,"href":"https:\/\/evaggelatos.com\/index.php?rest_route=\/wp\/v2\/posts\/20726\/revisions"}],"predecessor-version":[{"id":20729,"href":"https:\/\/evaggelatos.com\/index.php?rest_route=\/wp\/v2\/posts\/20726\/revisions\/20729"}],"wp:attachment":[{"href":"https:\/\/evaggelatos.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/evaggelatos.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/evaggelatos.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}